Clinical studies recruiting near Aviano

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · CRO-IRCCS ( Site 1808) · Merck Sharp & Dohme LLC · NCT06393374 Clinical Trial on Bowel Preparation Comparing Mannitol 100g to Plenvu Both in a Same Day Regimen (CLEARWAY)
Phase 3 · Centro Di Riferimento Oncologico Di Aviano · NTC srl · NCT07465705 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Irccs Centro Di Riferimento Oncologico (CRO) · Hoffmann-La Roche · NCT06793215 Observational Study on Skeletal Ewing's Sarcoma
Phase N/A · Centro di Riferimento Oncologico - Unit of Medical Oncology · Italian Sarcoma Group · NCT04845893 Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormon
Phase N/A · Centro di Riferimento Oncologico IRCCS · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06805812 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena
Phase 3 · CRO-IRCCS ( Site 2014) · Merck Sharp & Dohme LLC · NCT07216703 Visugromab in Cachexia International Trial
Phase 2/Phase 3 · Centro Riferimento Oncologico - Aviano · CatalYm GmbH · NCT07112196 Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer
Phase 4 · Centro di Riferimento Oncologico (CRO) IRCCS · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06726291 A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · Cro-Irccs · Pfizer · NCT07144280 A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Wit
Phase 3 · CRO-IRCCS-Clinical Oncology ( Site 1510) · Merck Sharp & Dohme LLC · NCT06077760 Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal
Phase N/A · Centro di Riferimento Oncologico · International Extranodal Lymphoma Study Group (IELSG) · NCT05700149 A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Phase 3 · Research Site · AstraZeneca · NCT07205822 Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
Phase 3 · Aviano - Centro Riferimento Oncologico - S.O.C. Oncologia Me · Fondazione Italiana Linfomi - ETS · NCT04442412 Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer
Phase N/A · Centro di Riferimento Oncologico (CRO) - IRCCS Aviano · Centro di Riferimento Oncologico - Aviano · NCT07397624 Identification of Biomarkers of Risk for Pre-neoplastic and Neoplastic Lesions for the Development of Gastric Cancer
Phase N/A · Centro di Riferimento Oncologico (CRO) di aviano-IRCCS · Centro di Riferimento Oncologico - Aviano · NCT07374731 DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
Phase 3 · Centro di riferimento Oncologico · Boehringer Ingelheim · NCT07472517 Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
Phase N/A · Centro Riferimento Oncologico CRO · Italian Sarcoma Group · NCT06375941 A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Ly
Phase N/A · IRCCS Centro di Riferimento Oncologico di Aviano - Divisione · Fondazione Italiana Linfomi - ETS · NCT06008691 A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Phase 3 · Centro di Riferimento Oncologico (CRO) · Verastem, Inc. · NCT06072781 Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · Centro Di Riferimento Oncologico · Revolution Medicines, Inc. · NCT06128551 Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute
Phase N/A · Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS · Centro di Riferimento Oncologico - Aviano · NCT06180005 Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Th
Phase N/A · Centro di riferimento oncologico - CRO di Aviano · Consorzio Oncotech · NCT06836219 Vitamin D and Head and Neck Cancer: Impact on Toxicity and Prognosis
Phase N/A · Centro di Riferimento Oncologico - Aviano · Centro di Riferimento Oncologico - Aviano · NCT05817617 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · Clinical Trial Site · Olema Pharmaceuticals, Inc. · NCT06016738 (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Phase 3 · Centro Riferimento Oncologico - Aviano · Cogent Biosciences, Inc. · NCT05208047 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherap
Phase 2/Phase 3 · Centro Di Riferimento Oncologico /ID# 276923 · AbbVie · NCT07155187 Immune Microenvironment and Gene Expression Profiling in Mesothelioma
Phase N/A · Centro di Riferimento Oncologico (CRO) IRCCS · Istituto Oncologico Veneto IRCCS · NCT06581549 Global Trial in APG2575 for Patients With CLL/SLL
Phase 3 · Ascentage Investigative Site · Ascentage Pharma Group Inc. · NCT06104566 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · IRCCS CRO Aviano, Hematology/Oncology ( Site 1957) · Merck Sharp & Dohme LLC · NCT03486873 Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Phase N/A · Novartis Investigative Site · Novartis Pharmaceuticals · NCT07093801

Look up another city

Look up another condition